Scholar Rock Holding (SRRK) Stock
Specialist biotech developing targeted treatments for serious conditions. Here's the price, business snapshot, and what's worth knowing about Scholar Rock Holding in October 2026.
Scholar Rock Holding Corp (SRRK) is a clinical‑stage biopharmaceutical company focused on developing therapies that modulate the transforming growth factor‑beta (TGF‑β) signalling pathway. The company’s pipeline targets conditions where TGF‑β is implicated, with several clinical programmes progressing through trials. As a specialist biotech, Scholar Rock’s value is shaped heavily by clinical results, regulatory decisions and partnerships rather than current product revenues. With a market capitalisation around $2.7 billion, the stock can offer exposure to potential upside from successful trials but also carries typical biotech risks: trial setbacks, regulatory hurdles and cash burn needing future financing. Investors should consider time horizon, risk tolerance and the binary nature of clinical catalysts. This summary is for educational purposes only and is not personalised investment advice; investors should conduct further research or consult an authorised financial adviser before acting.
Scholar Rock Holding (SRRK) Stock Forecast
Analyst price target, next 12 months
$57.71
+39.1% vs today's $41.49
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Scholar Rock Holding have a consensus 12-month target of $57.71, above the current price of $41.49.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Scholar Rock's stock, with a target price indicating significant growth potential.
Financial Health
Scholar Rock is performing well with its cash flow and book value, indicating strong financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage drug focus
The company’s value hinges on clinical readouts and scientific validation, which can create material share‑price moves; outcomes are uncertain.
Pipeline catalysts ahead
Upcoming trial milestones and partnerships can drive momentum, though any positive prospects may be offset by trial or regulatory disappointment.
Regulatory and cashflow
Regulatory approvals and financing decisions will shape long‑term prospects; investors should watch cash runway and funding plans carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.